O'Connor AB, et al. - Experts aspired to identify the variables associated with treatment retention in women 6 and 12 months postpartum, that were in medication treatment using buprenorphine during pregnancy. They found an association between early access to medication treatment and treatment retention in women prescribed buprenorphine during pregnancy. Since access to treatment was limited in many parts of the country and many women were only able to obtain treatment after becoming pregnant, this had important public health implications. During pregnancy, being prescribed an antidepressant medication could enhance treatment retention.